Biohaven Pharmaceutical Holding Co. Ltd. priced an underwritten public offering of 3,355,705 common shares at $37.25 apiece.
Gross proceeds from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company.
Underwriters have a 30-day option to purchase up to an additional 503,355 common shares at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on Dec. 17, subject to customary closing conditions.
Goldman Sachs & Co. LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with Morgan Stanley and Cantor Fitzgerald & Co. as book runners and William Blair as co-manager.
New Haven, Conn.-based Biohaven Pharmaceutical Holding is a clinical‑stage biopharmaceutical company which develops product candidates targeting migraine and neurological diseases, including rare disorders.